THE DEAL, AT A GLANCE
From the announcementCarmot Therapeutics
01Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedCarmot Therapeutics raised $150M Series EFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersCarmot Therapeutics is positioned around CT-388 as an AI-designed dual GIP/GLP-1 agonist for obesity, with Series E capital intended to move the asset into Phase 3 and…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Carmot Therapeutics · Financing Record
Explore source-linked visual explanations for Carmot Therapeutics. Unsupported claims are withheld while source review continues.
Record 1306 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →